摘要
目的研究柔肝化纤颗粒抗肝纤维化的作用及其机制。方法采用四氯化碳(CCl4)复合法大鼠肝纤维化模型,以秋水仙碱及大黄虫丸为对照,观察治疗前后血清卵泡抑素(FS)、肝组织病理学、激活素A(ACT A)表达及肝细胞凋亡的影响。结果与病理模型组大鼠相比,柔肝化纤颗粒治疗组纤维化分级、ACT A的表达、肝细胞的凋亡低于模型组;各治疗组血清FS水平均显著高于模型组。结论柔肝化纤颗粒对肝纤维化大鼠具有明显的抗肝纤维化作用,其作用机制可能与调控ACT A和FS表达有关,从而减少肝细胞的凋亡,促进肝细胞再生。
Objective To study the effect of Rouganhuaqiankeli against hepatic fibrosis and its mechanism of action. Methods Using carbon tetrachloride complex method for rat model of hepatic fibrosis, with colchicine and Dahuang Zhechong pill for con- trol. To observe serum follistatin,liver histopathology, activin A expression and liver cell apoptosis before and after treatment Resuits The rats in the model group compared with pathology, liver fiber particles treated fibrosis grade, ACT A expression,hepatic cell apoptosis compared with model group;each treatment group serum FS were significantly higher than in the model group. Conclusion Rouganhnaqiankeli on hepatic fibrosis in rats has obvious anti hepatic fibrosis ; its mechanism may be related to regulation of ACT A and FS expression, thereby reducing hepatic cell apoptosis, promoting regeneration of liver cell.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2012年第11期2705-2707,共3页
Lishizhen Medicine and Materia Medica Research
基金
广西壮族自治区自然科学基金(No.2010GXNSFA013211)
